Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Adverum Biotechnologies (GB:0HA3)
LSE:0HA3
RESEARCH TOOLSreports
Holding GB:0HA3?
Track your performance easily
0HA3 Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.61 - $29.50
Previous Close$4.76
Volume171.00
Average Volume (3M)1.41K
Market Cap
$98.60M
Enterprise Value$18.63M
Total Cash (Recent Filing)$153.24M
Total Debt (Recent Filing)$73.26M
Price to Earnings (P/E)―
Beta0.65
Next Earnings
Mar 26, 2025EPS Estimate
-$1.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.03
Shares Outstanding20,802,463
10 Day Avg. Volume1,960
30 Day Avg. Volume1,405
Standard Deviation0.24
R-Squared0.01
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.68
Price to Sales (P/S)98.60
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue18.63
Enterprise Value/Gross Profit5.17
Enterprise Value/Ebitda-0.21
Forecast
1Y Price Target
$21.00Price Target Upside341.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Adverum Biotechnologies News
PremiumCompany Announcements
Adverum Biotechnologies Advances Ixo-vec Gene Therapy Trials
PremiumPre-Earnings
Is ADVM a Buy, Before Earnings?
PremiumCompany Announcements
Adverum Biotechnologies Advances in Gene Therapy Development
Bulls Say, Bears Say
Bulls Say
Collaboration And InterestThere have been new collaboration agreements in the ADAR space, indicating growing interest and potential for partnerships.
Emerging TherapeuticsADAR-based therapeutics represent an exciting emerging class of genetic medicines, with applications in many therapeutic areas.
Gene Therapy AdvancementsThe new data for ixo-vec, a gene therapy candidate, is considered very robust on both safety and efficacy, supporting its best-in-class profile.
Bears Say
Competition4D-150 is the most direct competitor to ADVM's ixo-vec, with a first Phase 3 study expected to begin in 1Q25.
EarningsThe price target has been adjusted from $20 to $16 due to the assumed cost of the newly disclosed first Phase 3 study and current cash considerations.
Financial PerformanceFinancing remains a near-term overhang, but ADVM has several non-dilutive options to consider in order to fund the ixo-vec Phase 3 program.
---
0HA3 FAQ
What was Adverum Biotechnologies’s price range in the past 12 months?
Adverum Biotechnologies lowest share price was $4.61 and its highest was $29.50 in the past 12 months.
What is Adverum Biotechnologies’s market cap?
Currently, no data Available
When is Adverum Biotechnologies’s upcoming earnings report date?
Adverum Biotechnologies’s upcoming earnings report date is Mar 26, 2025 which is in 94 days.
How were Adverum Biotechnologies’s earnings last quarter?
Adverum Biotechnologies released its earnings results on Nov 04, 2024. The company reported -$1.3 earnings per share for the quarter, beating the consensus estimate of -$1.307 by $0.007.
Is Adverum Biotechnologies overvalued?
According to Wall Street analysts Adverum Biotechnologies’s price is currently Undervalued.
Does Adverum Biotechnologies pay dividends?
Adverum Biotechnologies does not currently pay dividends.
What is Adverum Biotechnologies’s EPS estimate?
Adverum Biotechnologies’s EPS estimate is -$1.36.
How many shares outstanding does Adverum Biotechnologies have?
Adverum Biotechnologies has 20,802,464 shares outstanding.
What happened to Adverum Biotechnologies’s price movement after its last earnings report?
Adverum Biotechnologies reported an EPS of -$1.3 in its last earnings report, beating expectations of -$1.307. Following the earnings report the stock price went down -1.657%.
Which hedge fund is a major shareholder of Adverum Biotechnologies?
Among the largest hedge funds holding Adverum Biotechnologies’s share is Versant Venture Management, LLC. It holds Adverum Biotechnologies’s shares valued at 4M.
---
Adverum Biotechnologies Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.00 (341.18% Upside)
$21.00 (341.18% Upside)
Blogger Sentiment
Bullish
GB:0HA3 Sentiment 100%
Sector Average 71%
Sector Average 71%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.00%
12-Months-Change
Fundamentals
Return on Equity
-76.26%
Trailing 12-Months
Asset Growth
19.11%
Trailing 12-Months
Company Description
Adverum Biotechnologies
Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich's ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr. and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA.
---
0HA3 Stock 12 Month Forecast
Average Price Target
$21.00
▲(341.18% Upside)
Technical Analysis
Adverum Biotechnologies
―
AlloVir
―
EyePoint Pharmaceuticals
―
Fate Therapeutics
―
Meiragtx Holdings
―
Best Analysts Covering 0HA3
1 Year
1 Year Success Rate
2/13 ratings generated profit
1 Year Average Return
-40.52%
reiterated a buy rating last month
Copying Joon Lee's trades and holding each position for 1 Year would result in 15.38% of your transactions generating a profit, with an average return of -40.52% per trade.
---